MacroGenics (M55) Stock Overview
A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
M55 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
MacroGenics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.42 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.23 |
| 1 Month Change | 3.97% |
| 3 Month Change | 2.35% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 7.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| M55 | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 6.3% | 1.2% | 0.2% |
| 1Y | n/a | 17.0% | 12.2% |
Return vs Industry: Insufficient data to determine how M55 performed against the Swiss Biotechs industry.
Return vs Market: Insufficient data to determine how M55 performed against the Swiss Market.
Price Volatility
| M55 volatility | |
|---|---|
| M55 Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: M55's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine M55's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 293 | Eric Risser | www.macrogenics.com |
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs.
MacroGenics, Inc. Fundamentals Summary
| M55 fundamental statistics | |
|---|---|
| Market cap | CHF 216.76m |
| Earnings (TTM) | -CHF 83.06m |
| Revenue (TTM) | CHF 143.95m |
Is M55 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M55 income statement (TTM) | |
|---|---|
| Revenue | US$175.14m |
| Cost of Revenue | US$176.45m |
| Gross Profit | -US$1.30m |
| Other Expenses | US$99.75m |
| Earnings | -US$101.06m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.59 |
| Gross Margin | -0.74% |
| Net Profit Margin | -57.70% |
| Debt/Equity Ratio | 0% |
How did M55 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 03:46 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MacroGenics, Inc. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| "Etzer Darout | Barclays |